Article
Washington, DC-Unoprostone isopropyl 0.15% (Rescula, Novartis) may be a viable option for further lowering IOP in patients with advanced glaucoma whose disease is uncontrolled by maximum tolerated medical therapy, said Leslie S. Jones, MD.
Investigators highlight the risk of misdiagnosing geographic atrophy
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Aflibercept treat-and-extend regimen for neovascular AMD: 5-year outcomes
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
Bausch + Lomb announces launch of new intelligent Arise lens fitting system
FDA approves expanded label for fluocinolone acetonide intravitreal implant